Elyse M Cornett, Meskerem A Nemomsa, Bailey Turbeville, Matthew A Busby, Jessica S Kaye, Aaron J Kaye, JooHee Choi, Giovanni F Ramírez, Giustino Varrassi, Adam M Kaye, Alan D Kaye, James Wilson, Latha Ganti
An intranasal formulation of midazolam, Nayzilam, has been FDA-approved to treat intermittent, stereotypic episodes of frequent seizure activity. Nayzilam is easy to administer and can quickly treat seizures that occur outside of the hospital. The intra-nasal route of administration allows non-medical personal to administer the drug which makes it more accessible and user-friendly in the event of a seizure. Many studies have indicated quick cessation of seizures with Nayzilam compared to rectal diazepam, which has been the standard of care treatment...
2022: Health Psychology Research